Payment overview · 2025
General Payments
$3,289.14
122 reported records · 28 companies
Healthcare provider profile · identity verified
David S Silvers, M.D
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · PALM BEACH GARDENS, FL · NPI 1891739488
Verified facts
What the public records show
CMS Open Payments records show David S Silvers, M.D received $3,289.14 in general payments during 2025 across 122 reported records.
Neurocrine BioSciences, Inc. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Rytary by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Evrysdi as an associated drug or biological on 569 records involving 252 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Evrysdi by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Gocovri by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $414.77 | 12.6% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $336.77 | 10.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $277.75 | 8.4% | 11 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $274.86 | 8.4% | 16 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $239.28 | 7.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $237.61 | 7.2% | 12 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$202.45 | 6.2% | 7 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $120.51 | 3.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $118.81 | 3.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.00 | 3.2% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $98.11 | 3.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $93.21 | 2.8% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $80.50 | 2.5% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$79.30 | 2.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.32 | 2.4% | 4 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $75.09 | 2.3% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $71.47 | 2.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.38 | 2.1% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.49 | 1.8% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $43.70 | 1.3% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $37.05 | 1.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.51 | 1.0% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.91 | 0.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.65 | 0.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.08 | 0.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $21.55 | 0.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $21.36 | 0.7% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $20.65 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,185.26 | 120 |
| Education | $81.49 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22.39 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $414.77 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $277.75 | 11 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $274.86 | 16 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $255.28 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $233.96 | 9 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $202.45 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $158.83 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.83 | 7 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $120.51 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $118.81 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $105.00 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $80.50 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $80.50 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $78.78 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $77.32 | 4 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $75.09 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $70.38 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $63.65 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $57.49 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $56.45 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $41.66 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $37.05 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $32.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $29.56 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Evrysdi open payments reported associated product |
CMS Open Payments — General Payments 569 supporting records · 252 recipient NPIs · example record 1211488410 |
Evrysdi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 440 | 127 |
| Donepezil Hcl | Donepezil Hcl | 337 | 117 |
| Gabapentin | Gabapentin | 253 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 74 |
| Trazodone Hcl | Trazodone Hcl | 214 | 78 |
| Rivastigmine | Rivastigmine | 185 | 48 |
| Memantine Hcl Er | Memantine Hcl | 178 | 37 |
| Memantine Hcl | Memantine Hcl | 152 | 43 |
| Pregabalin | Pregabalin | 143 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 40 |
| Sertraline Hcl | Sertraline Hcl | 115 | 34 |
| Propranolol Hcl | Propranolol Hcl | 95 | 27 |
| Rytary | Carbidopa/Levodopa | 83 | 19 |
| Doxepin Hcl | Doxepin Hcl | 73 | 29 |
| Levetiracetam | Levetiracetam | 72 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 28 |
| Prednisone | Prednisone | 71 | 15 |
| Mirtazapine | Mirtazapine | 67 | 21 |
| Primidone | Primidone | 60 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 17 |
| Gocovri | Amantadine Hcl | 57 | suppressed |
| Lacosamide | Lacosamide | 52 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 43 | 14 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 15 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Levetiracetam Er | Levetiracetam | 37 | 16 |
| Rasagiline Mesylate | Rasagiline Mesylate | 34 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Droxidopa | Droxidopa | 31 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 30 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 30 | suppressed |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Lamotrigine Er | Lamotrigine | 26 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Xcopri | Cenobamate | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | suppressed |
| Firdapse | Amifampridine Phosphate | 16 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Keppra | Levetiracetam | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Evrysdi | Risdiplam | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trileptal | Oxcarbazepine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,289.14 · 122 records | Neurocrine BioSciences, Inc. | AUSTEDO XR, Apokyn, CREXONT, INBRIJA, INGREZZA, KISUNLA, NOURIANZ, NURTEC ODT, Ocrevus Zunovo, PONVORY, PRECIVITYAD2, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, REXULTI, Radicava, Rystiggo, SPINRAZA, Sunosi, Symbravo, TMS NeuroHealth Centers Inc., UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VYALEV, VYEPTI, WAKIX, Xeomin, ZAVZPRET, ZEPOSIA, Zilbrysq | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error